MWNA
SYRS

Marshall Wace North America’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Marshall Wace North America’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,651
Closed -$373K – 1445
2018
Q2 		$373K Buy
+3,651
New +$452K ﹤0.01% 1139
2017
Q4 		– Sell
-1,725
Closed -$259K – 1657
2017
Q3 		$259K Buy
+1,725
New +$324K ﹤0.01% 1151

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace North America's SYRS Position: Q3 2018 in Review

Marshall Wace North America sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2018, closing a stake of 3,651 shares — an estimated $373K sold.

Marshall Wace North America first reported a position in SYRS in Q3 2017 and held it in 2 quarters. The position peaked at $373K in Q2 2018. 76 funds tracked by Wall St. Rank hold SYRS as of Q3 2018.

  • Marshall Wace North America reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 3,651 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $373K.
  • Marshall Wace North America first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Marshall Wace North America's Syros Pharmaceuticals, Inc. Common Stock position peaked at $373K in Q2 2018.
  • 76 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.